Guardant Health, Inc. (NASDAQ:GH) Q1 2025 Earnings Call Transcript
Operator: Hello, everybody and welcome to the Guardant Health Q1 2025 Earnings Call. My name is Elliot, and I will be your coordinator today.
Guardant Health Inc. (GH)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 1,409,116 | $60,028,327 | -3% | 0.6% |
| 2. | 1,230,000 | $1,091,058 | 0.01% | ||
| 3. | Hurley Capital Charles Goldblum | 100 | $4,260 | 0% | |
| 4. | Bayforest Capital Theodoros Tsagaris | 214 | $0 | -97% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.82 | 2,187 | Officer | 12,722 | 2024-03-18 | Filing | |
| $32.78 | 750 | Officer | 5,193 | 2023-06-09 | Filing | |
| $32.68 | 2,231 | Officer | 4,443 | 2023-06-09 | Filing | |
| $26.15 | 8,600 | Officer, Director | 2,049,238 | 2023-03-15 | Filing | |
| $26.33 | 84,452 | Officer, Director | 2,040,638 | 2023-03-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $50.47 | 13,932 | Officer, Director | 2,188,740 | 2025-05-02 | Filing | |
| $52.57 | 354 | Officer, Director | 2,202,672 | 2025-05-01 | Filing | |
| $51.56 | 1,748 | Officer, Director | 2,203,026 | 2025-05-01 | Filing | |
| $50.91 | 3,445 | Officer, Director | 2,204,774 | 2025-05-01 | Filing | |
| $49.53 | 44,691 | Officer, Director | 2,208,219 | 2025-05-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,173,880 | $476,007,288 | 0.01% | |
| 2. | 5,061,011 | $215,599,068 | 0.19% | |
| 3. | 1,357,227 | $57,817,870 | 0.04% | |
| 4. | 1,356,990 | $57,767,064 | 0.74% | |
| 5. | 852,052 | $36,297,440 | 0.01% |
News See All
Guardant Health (GH) Rose Following Several Positive News Reports
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
10 Best Performing Mid Cap Stocks to Buy According to Analysts
On February 7, Simeon Hyman, Global Investment Strategist at ProShares Advisors, appeared on CNBC to discuss the upcoming jobs report and its expected impact on the market.
Guardant Health, Inc. (NASDAQ:GH) Q4 2024 Earnings Call Transcript
Operator: Good afternoon. Thank you for attending today's Guardant Health Q4 2024 Earnings Call. My name is Tamia and I will be your moderator for today's call.
10 Best Performing Healthcare Stocks So Far in 2025
Despite the ongoing craze surrounding the GLP-1 obesity drugs, the healthcare sector was a lagger last year.
Why These 15 Stocks Are Skyrocketing in 2025
Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward tech innovation.
10 Trending AI Stocks on Latest News and Ratings
Technology is advancing unprecedentedly, and physical AI seems to be the next leap forward.
Guardant Health (GH) Set To Dominate The Growing Liquid Biopsy Market
Guardant Health, Inc. (GH) is poised for long-term growth as its revenue projections and R&D spending paint a growth story consistent with some of the best names in the industry.
10 Most Promising Cancer Stocks According to Hedge Funds
According to the World Health Organization (WHO), cancer remains one of the leading causes of death globally, responsible for nearly 10 million deaths in 2020, or about one in six deaths worldwide.